This is a preliminary report on Biohaven Pharmaceuticals’s security posture. If you want in-depth, always up-to-date reports on Biohaven Pharmaceuticals and millions of other companies, consider booking a demo with us. UpGuard is the new standard in third-party risk management and attack surface management. Our security ratings engine monitors billions of data points each day.
Rimegepant (BHV-3000; formerly BMS-927711) is an investigational drug candidate for the treatment of migraine. Originally discovered at Bristol-Myers Squibb, it is currently under development by Biohaven Pharmaceuticals.